Retatrutide, a novel dual agonist of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) target, is demonstrating promising results in initial patient assessments . Ongoing inquiry https://socialwebnotes.com/story6511758/retatrutide-emerging-investigations-and-potential-clinical-applications